Treatment
Participants were randomized 1:1 to one of two treatment sequences using the interactive web response system (Study design. *During each treatment period, four 40-min MWT sessions were performed at 2, 4, 6, and 8 h after the start of infusion. Each MWT session was followed by administration of the KSS and then the PVT. †During each treatment period, blood for PK analysis of danavorexton (and its metabolites) was obtained before infusion, at 1, 3, 5, 7, and 9 h after start of infusion, and at 0.17, 1, 4, and 15 h after the end of the infusion on day 1. The 15-h post-dose assessment was on day 2. ESS, Epworth Sleepiness Scale; IV, intravenous; KSS, Karolinska Sleepiness Scale; MWT, maintenance of wakefulness test; nPSG, nocturnal polysomnography; PK, pharmacokinetic; PVT, psychomotor vigilance task.